Jacques Moisan

Therapeutics, Jacques Moisan leads the group responsible for preclinical pharmacology testing of biotherapeutic candidates to help understand optimal design and key mechanistic insight into the unique T cell activation profile of Marengo’s novel STAR platform. He brings 14 years of experience in the biopharmaceutical industry to Marengo, overseeing teams driving concept through molecule screening and regulatory filing. Starting his career at AstraZeneca developing biologics for rheumatological indications, he soon made the transition to the immune-oncology field helping to build and shape multiple checkpoint inhibitor programs as well as T cell agonist approaches. Jacques then joined Lycera, a biotech company developing oral small molecule RORgamma agonists which was part of an exclusive global collaboration agreement with Celgene in 2015. Joining EMD Serono in 2016, Jacques contributed to shape the immune-oncology pipeline and team growth with increasing responsibility finishing with accountability for the T and NK discovery space within the Oncology/Immuno-oncology research department. Throughout his tenure at EMD Serono, he oversaw multiple IND filings and also authorship on numerous patents and publications.

Jacques holds a Ph.D. in Experimental Medicine from McGill University and completed his postdoctoral training at the Brigham and Women’s Hospital with affiliation to Harvard Medical School.